In the context of nanomedicine development, AI and ML can be applied in a variety of ways. This may include prediction of formulation properties and in vitro performance a priori, integration with highthroughput experimental methodologies to produce so-called "self-driving labs" , and directing the design of new formulations and biocompatible materials. One of the most challenging aspects of nanoformulation development is quantifying the interaction between API and excipients and mapping these interactions to the performance of the resulting advanced drug formulations. Despite advances made in the development and application of nanomedicines to date, a comprehensive understanding of how the chemical structure of excipients and drugs interact to afford desirable physicochemical properties of formulations remains an open problem. Similar problems have been overcome in drug discovery using quantitative structure-activity relationships (QSAR). These empirical models are used to find statistical correlations between chemical structure and receptor activity . Increasingly, traditional QSAR models with ML algorithms are being used to improve data processing . Following this lead, a similar approach in the pharmaceutical sciences could improve our understanding of advanced drug delivery systems, thereby uncovering new knowledge and paving a path towards more innovative drug delivery systems. Indeed, this has been the subject of past investigations, as it is expected that more widespread use of QSAR methods in nanomedicine, in tandem with AI/ML tools, will bolster their clinical translation .